Clinical Trial: Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients

U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07933653) titled 'Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients' on Nov. 04.

Brief Summary: To evaluate the efficacy and safety of oral thalidomide for the prevention of radiation-induced dermatitis (RID) in breast-conserving surgery patients receiving intensity-modulated whole-breast radiotherapy. This is a single-center randomized controlled trial. Female breast cancer patients aged >18 and =2 RID within the observation window. Secondary endpoints include incidence of grade >=3 RID, time-to-first-onset of grade >=2 RID, RID-related symptoms (burning, pruritus, pulling pain, tenderness), quality-of-life measured b...